American Realty Capital Propert (ARCP) 8.60 $ARCP Fitch

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 7:13 AM

American Realty Capital Propert (ARCP) 8.60 $ARCP

Fitch Affirms DBCCRE 2014-ARCP
BusinessWire - Wed Oct 28, 1:08PM CDT
Fitch Ratings has affirmed all classes of DBCCRE 2014-ARCP Mortgage Trust Commercial Mortgage Pass-Through Certificates. A complete list of rating actions is listed at the end of this release.
ARCP: 8.60 (-0.09)

How VEREIT Plans to Rise Out of the Ashes of ARCP
Dave Koppenheffer, The Motley Fool - Motley Fool - Mon Aug 10, 12:40PM CDT
On Thursday, VEREIT (NYSE: VER), formerly American Realty Capital Properties, conducted its second quarter conference call and CEO Glenn Rufrano discussed the four pillars to rebuild the company's foundation for the future. Enhance the...
WPC: 65.84 (-0.81), NNN: 49.92 (-0.18), O: 65.74 (+0.01), ARCP: 8.60 (-0.09)

VEREIT(TM) New Corporate Name for American Realty Capital Properties
PR Newswire - Tue Jul 28, 5:00AM CDT
As part of its ongoing efforts to focus on the future, American Realty Capital Properties, Inc. (NASDAQ: ARCP) announced that it will officially begin business operations under a new corporate name and will be known as VEREIT, Inc. ("VEREIT" or the "Company"

effective today.
ARCP: 8.60 (-0.09)

Technical Recap on REIT - Diversified Stocks -- Annaly Capital Management, American Realty Capital Properties, Spirit Realty Capital, Redwood Trust, and RAIT Financial Trust
PR Newswire - Thu Jul 16, 8:05AM CDT
Equity Research Institute has initiated coverage on the following equities: Annaly Capital Management Inc. (NYSE: NLY), American Realty Capital Properties Inc. (NASDAQ: ARCP), Spirit Realty Capital Inc. (NYSE: SRC), Redwood Trust Inc. (NYSE: RWT), and RAIT Financial Trust (NYSE: RAS). Free research report on Annaly Capital Management can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=NLY On Wednesday, July 15, 2015, the NASDAQ Composite ended at 5,098.94, down 0.12%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 18,050.17, and the S&P 500 closed at 2,107.40, down 0.07%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
NLY: 10.71 (unch), RWT: 14.30 (-0.50), ARCP: 8.60 (-0.09), RAS: 3.02 (-0.12), SRC: 13.23 (-0.02)

American Realty Capital Properties Announces Annual Meeting and Stockholder Record Dates
PR Newswire - Thu Jul 09, 5:45AM CDT
The Board of Directors of American Realty Capital Properties, Inc. (NASDAQ: ARCP) ("ARCP" or the "Company"

has scheduled the Company's 2015 Annual Meeting of Stockholders (the "Annual Meeting"

for Tuesday, September 29, 2015. Stockholders of record as of the close of business on Thursday, August 6, 2015 will be entitled to notice of and to vote at the Annual Meeting. Because the September 29, 2015 Annual Meeting date is more than 30 days after the anniversary of the Company's 2014 Annual Meeting of Stockholders, the deadline for submitting stockholder proposals made pursuant to Rule 14a-8 ("Rule 14a-8"

of the Securities Exchange Act of 1934, as amended, and for non-Rule 14a-8 stockholder proposals has been extended.
ARCP: 8.60 (-0.09)

Why American Realty Capital (ARCP) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 26, 7:30AM CDT
American Realty Capital is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
ARCP: 8.60 (-0.09)

American Realty Capital Properties Announces Monthly Series F Preferred Stock Dividend for July and August 2015
PR Newswire - Fri Jun 19, 3:05PM CDT
American Realty Capital Properties, Inc. ("ARCP"

(NASDAQ: ARCP) announced today that, pursuant to the authorization of its board of directors, it will pay a monthly dividend to holders of its 6.70% Series F Cumulative Redeemable Preferred Stock, par value $0.01 per share ("Series F Preferred Stock"

, in respect of the period commencing June 15, 2015 through July 14, 2015 on July 15, 2015 (the "July Series F Dividend"

and in respect of the period commencing July 15, 2015 through August 14, 2015 on August 17, 2015 (the "August Series F Dividend"

. Holders of Series F Preferred Stock on July 1, 2015 and on August 1, 2015 will be eligible to receive the July Series F Dividend and the August 2015 Series F Dividend, respectively. The dividend for the Series F Preferred Stock accrues daily on a 360-day annual basis equal to an annualized dividend rate of $1.675 per share, or $0.1395833 per 30-day month.
ARCP: 8.60 (-0.09)

Stocks to Watch: Diversified REITs
Dave Koppenheffer, The Motley Fool - Motley Fool - Thu Jun 18, 9:10AM CDT
Most real estate investment trusts stick to owning just one type of real estate, but diversified REITs are more dynamic and unrestrained in the types of real estate they pursue. For the right companies, this wide-reaching approach can create both...
VNO: 102.95 (-0.36), ARCP: 8.60 (-0.09)

American Realty Capital Properties Announces Appointment of Mark S. Ordan as Additional Independent Director
PR Newswire - Wed Jun 17, 3:05PM CDT
American Realty Capital Properties, Inc. (NASDAQ: ARCP) ("ARCP" or the "Company"

announced the appointment of Mark S. Ordan as an Independent Director and a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Company's Board of Directors (the "Board"

effective today.
ARCP: 8.60 (-0.09)

William C. Miller Named President and CEO of Cole Capital®
PR Newswire - Fri Jun 12, 8:00AM CDT
American Realty Capital Properties, Inc. (NASDAQ: ARCP) ("ARCP" or the "Company"

and Cole Capital, ARCP's investment management business, announced today the appointment of William C. Miller as President and Chief Executive Officer of Cole Capital and Executive Vice President, Investment Management for ARCP. Mr. Miller reports directly to Glenn J. Rufrano, ARCP's Chief Executive Officer, and also serves on the Company's senior management team.
ARCP: 8.60 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...